Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

NCT03392389 ·Status: COMPLETED ·Phase: PHASE1

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

NCT04652102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

NCT05960097 ·Status: COMPLETED ·Phase: PHASE2

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

NCT05894525 ·Status: COMPLETED

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

NCT05894590 ·Status: COMPLETED

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

NCT05137236 ·Status: COMPLETED ·Phase: PHASE2

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

NCT05876377 ·Status: ACTIVE_NOT_RECRUITING

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348 ·Status: COMPLETED ·Phase: PHASE1

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

NCT05477186 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

NCT06237296 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

NCT04649151 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

NCT04798001 ·Status: UNKNOWN ·Phase: PHASE1

Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine

NCT05249816 ·Status: COMPLETED ·Phase: PHASE3

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

NCT04452318 ·Status: COMPLETED ·Phase: PHASE3

SafeTy and Efficacy of Preventative CoVID Vaccines

NCT05208983 ·Status: UNKNOWN

A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

NCT02298179 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of NVX-CoV2705

NCT07086222 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

NCT04614948 ·Status: COMPLETED ·Phase: PHASE3

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

NCT06134648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

NCT04283461 ·Status: COMPLETED ·Phase: PHASE1

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

NCT04368728 ·Status: COMPLETED ·Phase: PHASE2/PHASE3